Mirtazapine in the Treatment of Adolescents with Major Depression: An Open-Label, Multicenter Pilot Study
- 1 June 2004
- journal article
- review article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 14 (2) , 175-184
Abstract
This multicenter, open-label study with a duration of 85 days was performed to evaluate the antidepressant efficacy and safety of mirtazapine (dose range, 30–45 mg) in 12–18-year-old adolescents diagnosed with major depression. Twenty-four (24) patients (15 female patients and 9 male patients) meeting the DSM-IV criteria for major depression and the Hamilton Rating Scale for Depression (HAM-D-17) score of 18 at baseline were enrolled in the study. The primary outcome measures were HAM-D-17, Beck Depression Inventory (BDI), and Clinical Global Impression (CGI) scales. Any changes in symptoms of anxiety were measured using the Hamilton Anxiety Rating Scale (HAM-A). The average age of the 23 subjects, who were eligible for analysis, was 16.3 years (standard deviation (SD) 6.11, median 17.3). The mean daily dose of mirtazapine was 32.9 mg. Mirtazapine showed a marked efficacy on all rating scales and was well tolerated. Mirtazapine had a beneficial effect on sleep. A rapid onset of sleep and pattern of action was seen. No dropouts due to adverse events were recorded. The most common treatment-emergent adverse events were tiredness, increased appetite, and dizziness. The results of this study suggest that mirtazapine may be an effective treatment for major depression in adolescents.Keywords
This publication has 32 references indexed in Scilit:
- Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action StudyJournal of Clinical Psychopharmacology, 2003
- Sertraline Effects in Adolescent Major Depression and Dysthymia: A Six-Month Open TrialJournal of Child and Adolescent Psychopharmacology, 2001
- The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents.Journal of Consulting and Clinical Psychology, 1999
- MirtazapineThe Journal of Clinical Psychiatry, 1998
- A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depressionEuropean Neuropsychopharmacology, 1995
- A multicentre, double‐blind, clomipramine‐controlled efficacy and safety study of org 3770Human Psychopharmacology: Clinical and Experimental, 1995
- Fluvoxamine in the treatment of depressive illness in children and adolescentsJournal of Psychopharmacology, 1994
- Methodology of Antidepressant Drug Trials for Treating Depression in AdolescentsJournal of Child and Adolescent Psychopharmacology, 1992
- Psychopharmacology of Child and Adolescent Major Depression: Present Status and Future DirectionsJournal of Child and Adolescent Psychopharmacology, 1992
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959